Who are Bis-Choline Tetrathiomolybdate's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): D-Penicillamine, trientine dihydrochloride, copper histidinate, ParaGard®, Penicillamine (W12-W60), Penicillamine (D1-W12).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bis-choline-tetrathiomolybdate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Bis-Choline Tetrathiomolybdate — Competitive Intelligence Brief

Bis-Choline Tetrathiomolybdate (Bis-Choline Tetrathiomolybdate) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chelating agent. Area: Neurology.

phase 2 Chelating agent Copper Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Bis-Choline Tetrathiomolybdate (Bis-Choline Tetrathiomolybdate) — Alexion Pharmaceuticals, Inc.. Bis-Choline Tetrathiomolybdate is a chelating agent that binds to copper, reducing its availability for incorporation into ceruloplasmin and subsequent deposition in the brain.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Bis-Choline Tetrathiomolybdate TARGET	Bis-Choline Tetrathiomolybdate	Alexion Pharmaceuticals, Inc.	phase 2	Chelating agent	Copper
D-Penicillamine	D-Penicillamine	Orphalan	marketed	Heavy metal chelator / immunosuppressant	Heavy metals (copper, mercury, lead); disulfide bonds in proteins
trientine dihydrochloride	trientine dihydrochloride	Univar BV	marketed	Copper chelator	Copper (Cu2+)
copper histidinate	copper histidinate	Sentynl Therapeutics, Inc.	marketed	Trace element supplement	Copper ion (Cu2+)
ParaGard®	ParaGard®	FHI 360	marketed	Intrauterine contraceptive device (copper IUD)	Copper ion-mediated spermicidal and anti-implantation effects
Penicillamine (W12-W60)	Penicillamine (W12-W60)	Orphalan	phase 3	Heavy metal chelator / immunomodulator	Copper, heavy metals (non-specific chelation); collagen cross-linking inhibition
Penicillamine (D1-W12)	Penicillamine (D1-W12)	Orphalan	phase 3	Chelating agent	Heavy metal ions (copper, mercury, lead); thiol-reactive compounds

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chelating agent class)

Ain Shams University · 1 drug in this class
Alexion Pharmaceuticals, Inc. · 1 drug in this class
M.D. Anderson Cancer Center · 1 drug in this class
Mt. Sinai Medical Center, Miami · 1 drug in this class
Orphalan · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Bis-Choline Tetrathiomolybdate — Competitive Intelligence Brief. https://druglandscape.com/ci/bis-choline-tetrathiomolybdate. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab